Navigation Links
Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
Date:9/18/2007

SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will participate in the UBS Global Life Sciences Conference.

UBS Global Life Sciences Conference

Grand Hyatt New York

Thursday, September 27, 2007

9:00 a.m. ET

The presentation will be audio webcast live and available for replay from Dendreon's website, http://www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
(Date:3/3/2015)... WASHINGTON , March 3, 2015 NASA astronaut ... his launch this month to spend a year living and ... live satellite interviews from 5:30 to 7 a.m. EDT Monday, ... Moscow as he completes the final weeks of ... by a video on NASA Television highlighting his mission training ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... CALGARY, Sept. 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... for metabolic and cardiovascular diseases, today announced that ... I/II human clinical trial of,plant-produced insulin now that ... (IND) application has passed. SemBioSys submitted,the application in ...
... - Cytochroma today announced that it,has appointed Steven ... and Quality Assurance. Dr. Engel brings to Cytochroma,over ... quality assurance,and will be responsible for directing all ... the Company has appropriate quality,systems in place. He ...
... Inc. (Nasdaq: BCRX ) today announced that Jon ... present,a corporate update at the UBS 2008 Global Life ... at 2:00 p.m. Eastern Time., A link to ... be accessed on,the BioCryst Web site http://www.biocryst.com . ...
Cached Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 3
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:3/2/2015)... Calif. , March 2, 2015 ... leading developer of human interface solutions, today announced ... that is designed to enable rapid and secure ... ID™ module for gaming is a turnkey solution ... the ability to quickly integrate fingerprint ID solutions ...
(Date:3/2/2015)...  Businesses have a new option for premier ... Enterprises has announced the launch of a brand ... businesses to protect their customers, personal data, as ... Beconux is a biometric transaction processing system recently ... an ATM machine, the new system fuses multiple ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2
... the University of Michigan Medical Center have, for the ... work indicates that these cells are likely responsible for ... this deadly cancer. , In the February 1 issue ... of these stem cells are needed to produce human ...
... to be genetically predisposed to developing severe depression, ... responsible. Now, a specific region rife with promise has ... researchers working under Douglas Levinson, MD, professor of ... of Medicine. , "This finding has a very good chance ...
... plant enzyme, researchers at the U.S. Department of Energy's Brookhaven ... of a temperate plant to the more saturated kind usually ... by the Proceedings of the National Academy of Sciences (PNAS) ... an unsaturated oil to an oil with increased saturated fatty ...
Cached Biology News:Scientists identify pancreatic cancer stem cells 2Scientists identify pancreatic cancer stem cells 3Stanford-led study closes in on genes that may predispose some people to severe depression 2Stanford-led study closes in on genes that may predispose some people to severe depression 3New success in engineering plant oils 2New success in engineering plant oils 3
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
... recombinant human angiogenin expressed in ... Physical form: Lyophilized from a ... phosphate buffered saline. Titertest ... Titertest values: capture ELISA ...
Request Info...
Biology Products: